MoonLake Immunotherapeutics (MLTX) AI Stock Analysis

• Market Cap: $2.59B
• Dividend Yield: N/A
• Average Volume (3M): 411.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.27
• Revenue Growth: N/A
• EPS Growth: -147.80%
• Country: US
• Employees: 100
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.63
• Shares Outstanding: 63,474,255
• 10 Day Avg. Volume: 369,248
• 30 Day Avg. Volume: 411,026
• PEG Ratio: 0.44
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -20.85
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: 14.06K
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -5.86
• 1Y Price Target: $76.09
• Price Target Upside: 88.90% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13

• Rating: 41 Neutral
• Price Target: ―

MoonLake Immunotherapeutics presents a high-risk, high-reward scenario typical for early-stage biotech firms. The strong balance sheet and recent financing provide a solid financial foundation, but the lack of revenue and operational losses weigh heavily on the score. Technical indicators are mixed, and the negative valuation metrics reflect the developmental nature of the company. The significant financing event is a positive catalyst, enhancing the company's ability to advance its pipeline.

Positive Factors

Clinical Development

MLTX reaffirmed their development plans for lead asset sonelokimab across multiple immuno-inflammatory diseases in dermatology and rheumatology.

Financial Performance

MoonLake's balance sheet along with the recent non-dilutive financing agreement with Hercules Capital is expected to fund operations into 2028.

Market Potential

Sonelokimab offers an attractive product profile across a number of multi-billion dollar indications and the stock has meaningful upside potential with a fast-approaching inflection point.

Negative Factors

Competitive Landscape

Long-term investors could potentially rescue the stock if 'HS = big' becomes the prevailing narrative.

Operational Risks

With enrollment risks & INCY povorcitinib risks in the rearview, it is believed that VELA 1 & 2 will dictate the fate of MLTX.

Stock Volatility

Even if efficacy lands at 21-22%, some near-term stock downside may occur.

MoonLake Immunotherapeutics Business Overview & Revenue Model

Company Description

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

How the Company Makes Money

MoonLake Immunotherapeutics makes money primarily through the development and commercialization of its proprietary drug candidates. The company generates revenue by advancing its therapeutic products through clinical trials and ultimately seeking regulatory approval for marketing and sales. Additionally, MoonLake may engage in strategic partnerships or collaborations with other pharmaceutical companies, which can include licensing agreements, joint ventures, or co-development opportunities to enhance its product pipeline and expand market reach. These partnerships can provide upfront payments, milestone payments, and royalties, contributing to the company's overall revenue. Furthermore, MoonLake might receive funding through grants, public offerings, or private investments to support its research and development activities.

MoonLake Immunotherapeutics Financial Statement Overview

Summary

MoonLake Immunotherapeutics is in an early-stage, pre-revenue phase, typical for a biotech company focused on R&D. Despite a strong balance sheet supported by equity funding, the absence of revenue and negative cash flows reflect the company's reliance on future product success and financing.

Income Statement

MoonLake Immunotherapeutics reported zero revenue over the past years, indicating a lack of commercialized products or services. This absence of revenue leads to an inability to calculate standard profitability metrics like Gross Profit Margin and Net Profit Margin. The persistent negative net income highlights ongoing operational losses, typical for a biotech company in its development phase.

Balance Sheet

The company's balance sheet shows a robust stockholders' equity position with a low level of debt, leading to a strong equity ratio. The Debt-to-Equity ratio is also favorable, indicating low financial leverage. However, the absence of revenue raises concerns about the sustainability of its equity and asset base without future revenue streams.

Cash Flow

The company exhibits significant negative free cash flow, which is typical for a biotech firm in the R&D phase. Financing activities have been substantial, suggesting reliance on external funding. However, the negative operating cash flow indicates the current lack of cash-generating operations, posing a risk if financing sources decline.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-13.16K	-12.36K	-4.97K	0.00
	EBIT
0.00	-54.12M	-65.06M	-53.58M	-105.76K
	EBITDA
-119.58M	-54.11M	-65.05M	-53.63M	-90.84K
	Net Income Common Stockholders
-120.68B	-36.01M	-64.51M	-53.64M	-90.84K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
448.03M	511.01M	72.11M	8.04M	1.34M
	Total Assets
477.93M	526.54M	76.84M	9.68M	116.63M
	Total Debt
2.83M	3.81M	282.58K	15.00M	58.06K
	Net Debt
-177.60M	-447.36M	-39.22M	6.96M	-1.28M
	Total Liabilities
24.54B	13.05M	8.08M	21.33M	4.15M
	Stockholders Equity
446.83B	495.68M	48.90M	-11.65M	112.48M
Cash Flow		Free Cash Flow
-117.11M	-43.06M	-55.91M	-35.23M	-316.69K
	Operating Cash Flow
-116.59M	-42.78M	-55.89M	-35.18M	-316.69K
	Investing Cash Flow
-205.60M	-25.18M	-32.34M	-50.71K	-115.00M
	Financing Cash Flow
51.31M	479.70M	119.69M	43.26M	116.65M

MoonLake Immunotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 40.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MLTX, the sentiment is Negative. The current price of 40.28 is above the 20-day moving average (MA) of 39.50, above the 50-day MA of 38.62, and below the 200-day MA of 45.84, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 48.62 is Neutral, neither overbought nor oversold. The STOCH value of 65.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MLTX.

MoonLake Immunotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FOLD	62 Neutral	$1.98B	―	-18.12%	―	28.25%	80.86%
Sector *	53 Neutral	$5.24B	3.07	-43.58%	2.80%	16.87%	-0.11%
APLS	50 Neutral	$2.33B	―	-103.82%	―	48.04%	48.16%
CRNX	46 Neutral	$2.94B	―	-30.84%	―	―	-1.20%
IMVT	45 Neutral	$2.55B	―	-74.17%	―	―	-43.10%
IBRX	43 Neutral	$2.47B	―	78.99%	―	10238.41%	47.67%
MLTX	41 Neutral	$2.59B	―	-30.57%	―	―	-147.80%

MoonLake Immunotherapeutics Corporate Events

MoonLake Immunotherapeutics Hosts Capital Markets Day

On April 29, 2025, MoonLake Immunotherapeutics will present an investor presentation during its Capital Markets Day event, detailing the company’s financial position, upcoming clinical developments, and strategic outlook. This presentation aims to provide stakeholders with insights into the company’s future direction and operational strategies, potentially impacting its market positioning and investor relations.

Spark’s Take on MLTX Stock

According to Spark, TipRanks’ AI Analyst, MLTX is a Neutral.

MoonLake Immunotherapeutics presents a high-risk, high-reward scenario typical for early-stage biotech firms. The strong balance sheet and recent financing provide a solid financial foundation, but the lack of revenue and operational losses weigh heavily on the score. Technical indicators are mixed, and the negative valuation metrics reflect the developmental nature of the company. The significant financing event is a positive catalyst, enhancing the company’s ability to advance its pipeline.

To see Spark’s full report on MLTX stock, click here.

MoonLake Immunotherapeutics Secures $500M Financing for Growth

On March 31, 2025, MoonLake Immunotherapeutics entered into a loan and security agreement with Hercules Capital for up to $500 million in non-dilutive financing. This agreement, which includes a $75 million initial draw, aims to support the company’s growth, including the advancement of sonelokimab and its expected launch in 2027. The financing enhances MoonLake’s financial position, allowing it to progress its clinical trials and prepare for commercial readiness without diluting shareholder equity. The company plans to provide further updates on its clinical programs and financial strategies at a Capital Markets Update on April 29, 2025.